Antitumor Effects of Carrier-Free Functionalized Lignin Materials on Human Hepatocellular Carcinoma (HepG2) Cells.
Yilin WangZhiqiang LuBin LiuFarzad SeidiChaofeng ZhangBo JiangCaoxing HuangHuining XiaoPeng WangYongcan JinPublished in: ACS nano (2024)
Lignin, as an abundant aromatic biopolymer in plants, has great potential for medical applications due to its active sites, antioxidant activity, low biotoxicity, and good biocompatibility. In this work, a simple and ecofriendly approach for lignin fractionation and modification was developed to improve the antitumor activity of lignin. The lignin fraction KL-3 obtained by the lignin gradient acid precipitation at pH = 9-13 showed good cytotoxicity. Furthermore, the cell-feeding lignin after additional structural modifications such as demethylation (DKL-3), sulfonation (SL-3), and demethylsulfonation (DSKL-3) could exhibit higher glutathione responsiveness in the tumor microenvironment, resulting in reactive oxygen species accumulation and mitochondrial damage and eventually leading to apoptosis in HepG2 cells with minimal damage to normal cells. The IC 50 values for KL-3, SL-3, and DSKL-3 were 0.71, 0.57, and 0.41 mg/mL, respectively, which were superior to those of other biomass extractives or unmodified lignin. Importantly, in vivo experiments conducted in nude mouse models demonstrated good biosafety and effective tumor destruction. This work provides a promising example of constructing carrier-free functionalized lignin antitumor materials with different structures for inhibiting the growth of human hepatocellular carcinoma (HepG2) cells, which is expected to improve cancer therapy outcomes.
Keyphrases
- ionic liquid
- oxidative stress
- endothelial cells
- cancer therapy
- reactive oxygen species
- healthcare
- cell cycle arrest
- cell death
- drug delivery
- risk assessment
- high resolution
- single cell
- type diabetes
- mesenchymal stem cells
- mouse model
- cell therapy
- cell proliferation
- insulin resistance
- climate change
- tandem mass spectrometry
- pluripotent stem cells
- glycemic control